Monday, September 23, 2013

Indi Molecular Gets $1.5M For Synthetic Antibodies

Seattle-based Indi Molecular, a developer of synthetic replacements for antibodies, has raised $1.5M in a seed funding round. The round was led by Interwest Partners, along with angels. The company--which has licensed technology from the Scripps Research Institute and the California Institute of Technology--said it is developing a potential replacement for antibodies, which it says are equivalent or superior to molecular antibodies. More information »